As of November 6, 2026, Arcus Biosciences, Inc. is a publicly traded company (NYSE: RCUS). The largest holder reporting an active stake on Schedule 13D is Gilead Sciences, Inc., at 24.7%. No bankruptcy or receivership appears in its SEC Form 8-K filings. Passive holders reporting on Schedule 13G include BlackRock (10.4%) (Schedule 13D/A, August 7, 2026).
Is this your company?
About to sign with, pay or invest in Arcus Biosciences, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Arcus Biosciences, Inc. a real, registered company?
- Arcus Biosciences, Inc. files with the SEC under CIK 1724521 (its SEC filings).
- Its shares are listed under the ticker RCUS on NYSE (SEC company record).
- Incorporated in Delaware; business address in Hayward, California, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Arcus Biosciences, Inc. in our court records and SEC 8-K records (as of 2026-11-06).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Gilead Sciences, Inc. (filed 2026-08-07).
Who are Arcus Biosciences, Inc.'s owners and officers?
Arcus Biosciences, Inc.: incorporated in Delaware; business address in Hayward, California; industry Pharmaceutical Preparations (Schedule 13D/A, 2026-08-07).
| Report | Holder | Share |
|---|---|---|
| Schedule 13D/A, 2026-08-07 | Gilead Sciences, Inc. | 24.7% |
| Schedule 13G/A, 2026-03-26 | The Vanguard Group | 0% |
| Schedule 13G/A, 2026-01-08 | Blackrock, Inc. | 10.4% |
| Schedule 13G/A, 2025-11-14 | Point72 Asset Management, L.P. | 4.1% |
| Schedule 13D/A, 2025-11-05 | Gilead Sciences, Inc. | 25.6% |
| Schedule 13D/A, 2025-07-15 | Gilead Sciences, Inc. | 29.7% |
Questions about who owns Arcus Biosciences, Inc.
Who owns Arcus Biosciences, Inc.?
On this page, 2 holders' latest ownership filings report 5% or more of Arcus Biosciences, Inc.: Gilead Sciences, Inc. (24.7%, Schedule 13D/A, filed 2026-08-07) and Blackrock, Inc. (10.4%, Schedule 13G/A, filed 2026-01-08).
Who are the largest shareholders of Arcus Biosciences, Inc.?
By the share each holder's latest filing reports, the largest holders of Arcus Biosciences, Inc. on this page are Gilead Sciences, Inc. (24.7%) and Blackrock, Inc. (10.4%).
When did Gilead Sciences, Inc. buy into Arcus Biosciences, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Gilead Sciences, Inc. on this page is the Schedule 13D/A, filed 2025-07-15, reporting 29.7%; its latest, Schedule 13D/A filed 2026-08-07, reports 24.7%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 6 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Arcus Biosciences, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Arcus Biosciences, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Arcus Biosciences, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
12 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own Arcus Biosciences, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , Inc., a 10% owner: 31,424,760 shares (21.8% of shares outstanding) (Form 4, 2025-02-20).
- , the chief executive and a director: 2,236,409 shares (1.6% of shares outstanding) (Form 4, 2026-01-26).
- , the president: 1,200,531 shares (0.83% of shares outstanding), 378,291 held directly and 822,240 indirectly (Form 4, 2026-07-13).
- , a director: 957,955 shares (0.67% of shares outstanding), 25,700 held directly and 932,255 indirectly (Form 4, 2026-06-12).
- , the chief operating officer: 224,024 shares (0.16% of shares outstanding) (Form 4, 2026-01-26).
Shares outstanding: 143,990,614 as of 2026-10-29, from the company's latest SEC cover page.
How much has Arcus Biosciences, Inc. raised?
No fundraising or offering filing from Arcus Biosciences, Inc. is on file with us.
Keep reading
More on Arcus Biosciences, Inc. and the records around it.
Arcus Biosciences, Inc. elsewhere on the record
- 5%+ stake filings Aug 2026
Companies that share a holder
- GILEAD SCIENCES, INC. also filed stake reports on 5 other companies: Aspen Neuroscience, Inc. (Nov 2026), ASSEMBLY BIOSCIENCES, INC. (May 2026), Arcellx, Inc. (Apr 2026)
- Point72 Asset Management, L.P. also filed stake reports on 90 other companies: Immunocore Holdings plc (Nov 2026), Target Hospitality Corp. (Nov 2026), E.W. SCRIPPS Co (Oct 2026)
- BlackRock, Inc. also filed stake reports on 1596 other companies: AvePoint, Inc. (Nov 2026), BIOMARIN PHARMACEUTICAL INC (Nov 2026), MSG RANGERS CORP (Nov 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/arcus-biosciences